cba logo1[1]
search
Join Us
Business Summary
Capital Raising

Investment in Indian pharma company

Mandate ID: IN-22-VGA-1-2205-3
Transaction Type:
Capital Raising

Industry: Pharmaceuticals


Sector: Healthcare


SIC Code: 51220308 PHARMACEUTICALS


Country of Origin: India | India


Target Countries: India


Target Areas: Worldwide


Capital Raising		 > Investment in Indian pharma company

Business Review

The company is an established player in the generic oncology space, in the business for 17+ years. It is into manufacturing and marketing of chemotherapy, haematology, supportive care and NDDS niche products.

Products

Main product offerings - chemotherapy range - Cisplatin, Carboplatin, Oxaliplatin, Doxorubicin, Etoposide, Cyclophosphamide, Ifosfamide,Flurouracil,Vincristine,Vinblastin,Leucovorin,Methotraxate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, daunorubicin, Pemetrexid, Fulvestrant, PFS, Caecitabine, Imatinib, Erlotinib, Dasatinb

Financial Information

Capital required: INR on request.


Revenue Multiple :


EBITDA Multiple :


Highlights

The company started as a drug marketing company and created a pan India presence in that space. Then it ventured into manufacturing and became an established player in the market. Its products are exported to 30 countries under emergency import permits and registration process is underway. The focus now is on creating a niche in NDDS and peptides. Also venturing into Liposomal delivery system and Nanoparticles.

Request More Information

CBA Cross Border Associates

More than 370 CBA Associates cross borders for you in in almost 100 countries

CBA International Ltd.
45 Albemarle Street, St. James
London W1, United Kingdom

This website uses cookies to enhance your browsing experience and ensure the site functions properly. By continuing to use this site, you acknowledge and accept our use of cookies.

Accept All Accept Required Only